Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral drugs Clear all
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

NCT00059462
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2 SA, HAART
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 14, 2026, 12:44 AM EDT
Terminated Phase 4 Interventional

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

NCT04249037
View directory record Official record
Conditions
HIV/AIDS
Interventions
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Not applicable Interventional Results available

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

NCT00709111
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 3 Interventional

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

NCT00008528
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 12:44 AM EDT
Not listed Phase 1 Interventional

An Electronic Pillbox for People With HIV

NCT00071500
View directory record Official record
Conditions
HIV Infections
Interventions
MedSignals™
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Switching From Epzicom to Truvada

NCT00724711
View directory record Official record
Conditions
HIV Infection
Interventions
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 14, 2026, 12:44 AM EDT
Terminated Not applicable Interventional

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

NCT00000875
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Diphenhydramine hydrochloride, Lymphocytes, Activated, Lamivudine, Zidovudine, Acetaminophen, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 14, 2026, 12:44 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
View directory record Official record
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 2 Interventional

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects

NCT00043953
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir mesylate, Lamivudine/zidovudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2007 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)

NCT01227590
View directory record Official record
Conditions
Drug Interactions, Human Immunodeficiency Virus
Interventions
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

NCT00040664
View directory record Official record
Conditions
HIV Infection
Interventions
ritonavir, fosamprenavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 2 Interventional

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

NCT00000891
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00002380
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 13 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 12:44 AM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 2 Interventional

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

NCT00001083
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 12:44 AM EDT
Terminated Not applicable Interventional

Computer-Assisted Adherence Program for Patients Taking Anti-HIV Drugs

NCT00051766
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Computer-based Intervention
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 12:44 AM EDT
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 14, 2026, 12:44 AM EDT
Withdrawn Phase 2 Interventional

PRO 140 for Human Immunodeficiency Virus

NCT02438345
View directory record Official record
Conditions
HIV
Interventions
PRO 140
Biological
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Phildadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 2 Interventional

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

NCT00000872
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Days to 2 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Gainesville, Florida • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers

NCT00103012
View directory record Official record
Conditions
Healthy
Interventions
Gingko Biloba, Echinacea purpurea, Panax ginseng
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Not applicable Interventional

Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV

NCT00339092
View directory record Official record
Conditions
HIV Infections
Interventions
Modified Directly Observed Therapy, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 14, 2026, 12:44 AM EDT
Completed No phase listed Observational

A Study of the Long-Term Outcomes of HIV-Positive Patients

NCT00000932
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
3,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
91
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 14, 2026, 12:44 AM EDT
Completed Phase 4 Interventional

Intermittent Versus Continuous Medication in the Treatment of HIV

NCT00001967
View directory record Official record
Conditions
HIV Infection
Interventions
HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 12:44 AM EDT